Cash Flow Statement

Cash from Financing Activities Cash from Operations Cash from Restructuring Change in Account Payables Change in Accured Expenses Change in Cash Change in Receivables Depreciation & Amortization (CF)Exchange Rate Effect Free Cash Flow Gains from Investment Securities Gains from Sales and Divestitures Net Cash Flow Net Income Non-cash Items Other Working Capital Changes Other financing activities Share-based Compensation

Daily Values

Growth Metrics

Others

Ratios

Neuphoria Therapeutics (NEUP) Cash from Restructuring (2025)

Historic Cash from Restructuring for Neuphoria Therapeutics (NEUP) over the last 1 years, with Q4 2025 value amounting to $1.2 million.